Latest News
Faeth Therapeutics, Inc.
- Faeth presents preclinical data on PIKTOR in breast cancer By Investing.com
- Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib
- Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 22, 2026
- Joe Cotton’s Weekly Stock Picks: Speculative biotechs — Faeth Therapeutics and Climb bio
- Citizens reiterates Faeth Therapeutics stock rating on cancer drug potential By Investing.com
- Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026
- Faeth Therapeutics to present PIKTOR preclinical data at ESMO
- Faeth Therapeutics (FTH) to Present Preclinical Data on PIKTOR a
- William Blair initiates Faeth Therapeutics stock with outperform rating By Investing.com
- SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition
- Citizens maintains Faeth Therapeutics stock rating on PIKTOR data
- Faeth Therapeutics: A Deep Dive (NASDAQ:FTH)
Headlines from the last 30 days, linking to the original publishers. See all market news →